This quarter has been an important one for Broken String. From our FDA Master File submission and commercial expansion into Southeast Asia, to the launch of our new brand and website, we’ve continued building towards a clear goal: helping therapy developers generate high-quality, genome-wide safety data earlier, faster, and in relevant cell systems.

Broken String Biosciences, today announced the submission of a Master File (MAF) to the U.S. Food and Drug Administration (FDA) for its INDUCE-seq® platform, marking a significant step in supporting regulatory adoption of genome-wide DNA break analysis in gene editing programs. 

Alongside rebranding, we have redesigned our website so researchers can easily access a comprehensive resource library and gain a clear understanding of how our INDUCE-seq platform can be applied across gene editing workflows to maximize value in development pipelines.

To drive the company’s commercial expansion, Terry Pizzie has been appointed as CEO, bringing extensive experience from leading and scaling global life science businesses.